Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
Arribas, José R, Dr, Girard, Pierre-Marie, MD, Landman, Roland, MD, Pich, Judit, PharmD, Mallolas, Josep, MD, Martínez-Rebollar, María, MD, Zamora, Francisco X, MD, Estrada, Vicente, MD, Crespo, Manuel, MD, Podzamczer, Daniel, MD, Portilla, Joaquín, MD, Dronda, Fernando, MD, Iribarren, José A, MD, Domingo, Pere, MD, Pulido, Federico, MD, Montero, Marta, MD, Knobel, Hernando, MD, Cabié, André, Prof, Weiss, Laurence, Prof, Gatell, José M, Prof
Published in The Lancet infectious diseases (01.07.2015)
Published in The Lancet infectious diseases (01.07.2015)
Get full text
Journal Article